China Becomes First Globally to Approve Takeda's Novel Narcolepsy Drug TAK-861
核心洞察
China's NMPA has granted the world's first market approval for TAK-861, an oral selective orexin receptor 2 (搜索) agonist for type 1 narcolepsy (搜索).
The drug was developed by Takeda (搜索) through multicenter global clinical trials involving participants from 19 countries and regions.
TAK-861 represents a novel mechanism targeting the underlying cause of narcolepsy, unlike existing therapies that only relieve symptoms.
China's National Medical Products Administration (NMPA) has become the first drug regulatory body in the world to grant market approval for TAK-861, an oral selective orexin receptor 2 (搜索) agonist developed by Takeda (搜索) for the treatment of type 1 narcolepsy (搜索). The approval covers adult patients and adolescents aged 16 and above, marking a historic milestone in China's pharmaceutical regulatory landscape.
The decision is particularly noteworthy because drug regulators from Japan and the United States have both accepted marketing applications for the same therapy and granted it priority review, yet China's NMPA was the first to issue market authorization. Historically, the vast majority of novel drugs have reached the market first in the United States or other developed countries.
"China's approval of the drug signals a historic breakthrough in the development, registration and market launch of highly innovative treatment," said Xu Xiaoqiang, an official with the NMPA, during an interview with Central China Television.
A Novel Mechanism Targeting the Root Cause
TAK-861 is an oral selective orexin receptor 2 (搜索) agonist that leverages a novel target and mechanism of action. Unlike currently available treatments, which primarily focus on relieving symptoms, TAK-861 is designed to address the underlying pathophysiology of type 1 narcolepsy (搜索).
Narcolepsy is a chronic, rare neurological disorder classified into two types. Its hallmark symptom is uncontrollable daytime sleepiness, with patients suddenly falling asleep while engaged in everyday activities such as talking, eating, or conversing. As a 24-hour sleep disorder, type 1 narcolepsy (搜索) patients may also experience cataplexy — a sudden loss of muscle control.
The disease has been included in China's second national list of rare diseases, with an estimated global prevalence of approximately 4 in 10,000. Adolescents and children account for a relatively large proportion of patients, and the condition, often accompanied by multiple complications, can severely affect their study, work, and daily life.
Limitations of Existing Therapies
Experts cited in reports note that existing treatments for this rare 24-hour sleep disorder mainly focus on relieving symptoms, while new therapies targeting the causes of the disease are urgently needed. Currently approved drugs worldwide have significant limitations, including limited efficacy and potential risks such as chronic organ damage, psychological or physical drug dependence, and cognitive decline.
Global Clinical Development
The newly approved drug underwent global multicenter clinical trials involving participants from 19 countries and regions, including adolescent patients. Clinical data demonstrated that TAK-861 can improve core symptoms of the disease and is expected to become a first-line treatment option in the future.
The drug was jointly developed and submitted for marketing approval globally across China, the United States, Japan, and other countries. The approval marks a breakthrough for China in the global development of innovative drugs, spanning the entire pathway from original target discovery and simultaneous international multicenter clinical trials to regulatory approval and market launch.